PA
ATNM icon

Pinnacle Associates’s Actinium Pharmaceuticals ATNM Stock Holding History

Pinnacle Associates’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-34,333
Closed -$272K – 765
2021
Q2 		$272K Buy
+34,333
New +$269K ﹤0.01% 666

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Pinnacle Associates's ATNM Position: Q3 2021 in Review

Pinnacle Associates sold out of Actinium Pharmaceuticals (ATNM) in Q3 2021, closing a stake of 34,333 shares — an estimated $272K sold.

Pinnacle Associates first reported a position in ATNM in Q2 2021 and held it in 1 quarter. The position peaked at $272K in Q2 2021. 43 funds tracked by Wall St. Rank hold ATNM as of Q3 2021.

  • Pinnacle Associates reported no remaining Actinium Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Pinnacle Associates sold 34,333 Actinium Pharmaceuticals shares in Q3 2021, an estimated $272K.
  • Pinnacle Associates first reported a position in Actinium Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Pinnacle Associates's Actinium Pharmaceuticals position peaked at $272K in Q2 2021.
  • 43 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2021.

Based on Pinnacle Associates's 13F filing for Q3 2021, filed 19 Oct 2021.